Last reviewed · How we verify
UDCA 250mg
UDCA 250mg, marketed by MinaPharm Pharmaceuticals, holds a established position in its therapeutic segment. The key composition patent, set to expire in 2028, provides a significant period of market exclusivity. The primary risk lies in potential generic competition post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | UDCA 250mg |
|---|---|
| Sponsor | MinaPharm Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia (PHASE4)
- A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones). (PHASE4)
- The Impact of Ursodeoxycholic Acid and Probiotics on Metabolic Outcomes in Type 2 Diabetic Patients Taking Metformin (PHASE1)
- Probiotics for Gallstones in Post-bariatric Surgery Patients (NA)
- Auto Transplant for High Risk or Relapsed Solid or CNS Tumors (NA)
- Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients (PHASE4)
- An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers (PHASE1)
- Effectiveness and Safety in Administrating CNU® Capsule to Refractory Functional Dyspepsia Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UDCA 250mg CI brief — competitive landscape report
- UDCA 250mg updates RSS · CI watch RSS
- MinaPharm Pharmaceuticals portfolio CI